Virtu Financial LLC Purchases 19,374 Shares of Vaccinex, Inc. (NASDAQ:VCNX)

Virtu Financial LLC boosted its position in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 103.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,026 shares of the company’s stock after acquiring an additional 19,374 shares during the quarter. Virtu Financial LLC’s holdings in Vaccinex were worth $106,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in Vaccinex during the first quarter worth $54,000. UBS Group AG acquired a new position in shares of Vaccinex in the first quarter valued at $86,000. State Street Corp acquired a new position in shares of Vaccinex in the second quarter valued at $188,000. Geode Capital Management LLC acquired a new position in shares of Vaccinex in the first quarter valued at $194,000. Finally, Telemetry Investments L.L.C. increased its holdings in shares of Vaccinex by 14.3% in the second quarter. Telemetry Investments L.L.C. now owns 120,000 shares of the company’s stock valued at $336,000 after purchasing an additional 15,000 shares during the last quarter. 5.27% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:VCNX opened at $1.66 on Thursday. Vaccinex, Inc. has a one year low of $1.50 and a one year high of $9.56. The company has a fifty day moving average of $2.06. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.10 and a current ratio of 6.86.

Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Monday, November 8th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.12.

Vaccinex Profile

Vaccinex, Inc operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease.

Featured Article: What is the Coverage Ratio?

Want to see what other hedge funds are holding VCNX? Visit to get the latest 13F filings and insider trades for Vaccinex, Inc. (NASDAQ:VCNX).

Institutional Ownership by Quarter for Vaccinex (NASDAQ:VCNX)

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with's FREE daily email newsletter.